
Worldwide, Total Mesorectal Excision (TME) has become the gold standard treatment for middle and lower rectal cancer. Studies have demonstrated a TME improves local recurrence rates and the corresponding survival by as much as 20%. High-quality TME surgery reduces local recurrence from 20% to 30% and increases 5-year survival from 48% to 68%. The June 2022 CTR Coding Break titled ‘STORE Manual 2022 Macroscopic Mesorectum’ discusses…